Proqr Therapeutics

04/06/2024

08/12/2023

Today ProQR has announced the transaction for Thea to acquire Sepofarsen and Ultevursen Ophthalmic Assets has been completed.

Press release here: https://bit.ly/46TZf0S

“Following previous announcements related to this transaction, we are pleased to share that we have now completed the divestment of the sepofarsen and ultevursen programs to Théa, who will continue the development of these potentially transformational therapies for patients with LCA10 and Usher Syndrome” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR.

ProQR has received an initial payment of €8M and may be eligible for up to €165M in further development, regulatory, and commercial earn-out payments upon related achieved milestones, as well as double-digit royalties based on commercial sales in the US and EU.

19/10/2023

Earlier this week, our Chief Scientific Officer Gerard Platenburg penned an article in BioSpace, explaining recent developments in and its potential to treat both rare genetic disorders and common conditions for patients in need.

Read more about his perspective on the strength and potential of , and why it’s widely considered the next generation of promising medicine here:
https://www.biospace.com/article/interest-in-rna-editing-accelerates-as-therapies-approach-the-clinic-/

If you want to learn more about Axiomer, visit our dedicated webpage: www.proqr.com/science/axiomer-technology or check out our short informative videos: www.youtube.com/watch?v=2KmGkQF24cQ&t=15s

The next frontier in RNA therapies, RNA editing has the potential to treat both genetic and common disorders, and the technology is rapidly expanding beyond the liver.

27/09/2023

Today we have provided an update that our previously announced agreement to divest the company’s late-stage ophthalmic assets to Théa has been terminated.

Read more:

ProQR is a clinical stage biotech company based in the Netherlands that discovers and develops unique RNA-based therapies for severe genetic disorders.